Bronchiolitis viruses after nirsevimab in infants
Part of Infections, Lungs & breathing clinical trials.
This study looks at how well the new nirsevimab vaccine works against bronchiolitis in babies. If your infant has their first bout of bronchiolitis and gets a nose swab, they may be able to help researchers understand how the virus spreads and how to better protect other babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is 12 months old or younger
- They were seen in the pediatric emergency room for their first case of bronchiolitis during winter 2024 to 2027
- A nasal swab was taken to test for viruses
- You agree to let them join and be contacted for follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows babies under 12 months old who are hospitalized with bronchiolitis to understand their treatment and outcomes. It includes tracking RSV testing and a new immunization called nirsevimab, which may help protect against severe illness.
This trial looks at how well the drug nirsevimab works for babies hospitalized with RSV bronchiolitis. It also studies the body's immune response and the baby's environment. The goal is to see if nirsevimab can help infants recover from this serious lung infection.
This study looks at how the germs in a baby's gut and their immune system respond to bronchiolitis (a common lung infection). If your baby is under 12 months and gets bronchiolitis during the RSV season, their participation could help us understand why some babies get very sick and others don't.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
Hear when a new Acute Bronchiolitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.